Wassim Noureddine, MD
Endocrinology, Diabetes & Metabolism · Jackson, MINPI 1548421167
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $793 of the $888 with a category attached, or 89.3%. 8 manufacturers reported payments, led by Medtronic at 28.2% of the total. Reporting peaked in 2023 at $325 and has fallen 61.3% since, to $126 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MI, where the typical reported total is $1,470.
Across 18 payments — averaging $49.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$250
- Amgen$213
- Corcept Therapeutics$125
- Insulet Corporation$113
- Novo Nordisk$89
- Pfizer$68
- plus $29 from 2 others
Across 24 payments — averaging $2659.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$48K
- Pfizer$16K
What the payments were for
- Food & beverage$79389%
- Education$9511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $250 |
| Amgen(2 entities) | 4 | $213 |
| Corcept Therapeutics | 1 | $125 |
| Insulet Corporation | 1 | $113 |
| Novo Nordisk | 2 | $89 |
| Pfizer | 2 | $68 |
| AbbVie | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$888 in reported general payments places this provider in the 40th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 234 | $302,212 |
| MounjaroTirzepatide | 228 | $281,440 |
| JardianceEmpagliflozin | 104 | $129,320 |
| TrulicityDulaglutide | 47 | $51,606 |
| JanuviaSitagliptin Phosphate | 63 | $51,523 |
| FarxigaDapagliflozin Propanediol | 53 | $51,257 |
| Teriparatide | 11 | $36,573 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $32,977 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 132 | $16,093 |
| Novolog FlexpenInsulin Aspart | 75 | $14,481 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $9,104 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $8,375 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,694 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 13 | $7,436 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $89 | $305,845249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Jackson
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.